Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Buy
61
SOPH Quote, Financials, Valuation and Earnings
Last price:
$5.04
Seasonality move
:
9.8%
Day range:
$4.93 - $5.18
52-week range:
$2.58 - $5.30
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
4.60x
P/B ratio:
5.61x
Volume:
101.2K
Avg. volume:
127.4K
1-year change:
47.86%
Market cap:
$340.6M
Revenue:
$65.2M
EPS (TTM):
-$1.12
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SOPH
SOPHiA GENETICS SA
|
$18.1M | -$0.20 | 15.57% | -12.05% | $7.33 |
|
ACIU
AC Immune SA
|
$994.8K | -$0.22 | 18.17% | -6.14% | $9.61 |
|
ADXN
Addex Therapeutics Ltd.
|
$242.8K | -- | 2.35% | -- | $30.00 |
|
CRSP
CRISPR Therapeutics AG
|
$9M | -$1.29 | -89.16% | -180.62% | $81.33 |
|
ONC
BeOne Medicines Ltd.
|
$1.4B | $0.86 | 30.35% | -70.04% | $401.52 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SOPH
SOPHiA GENETICS SA
|
$5.02 | $7.33 | $340.6M | -- | $0.00 | 0% | 4.60x |
|
ACIU
AC Immune SA
|
$2.88 | $9.61 | $289.7M | -- | $0.00 | 0% | 56.16x |
|
ADXN
Addex Therapeutics Ltd.
|
$8.38 | $30.00 | $7.8M | 0.77x | $0.00 | 0% | 35.97x |
|
CRSP
CRISPR Therapeutics AG
|
$58.18 | $81.33 | $5.5B | -- | $0.00 | 0% | 132.71x |
|
ONC
BeOne Medicines Ltd.
|
$331.40 | $401.52 | $36.7B | 637.68x | $0.00 | 0% | 7.40x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SOPH
SOPHiA GENETICS SA
|
51.08% | 1.943 | 19.62% | 2.45x |
|
ACIU
AC Immune SA
|
6.95% | 3.999 | 2.01% | 1.10x |
|
ADXN
Addex Therapeutics Ltd.
|
-- | 2.172 | -- | 4.36x |
|
CRSP
CRISPR Therapeutics AG
|
9.92% | 3.188 | 3.47% | 16.13x |
|
ONC
BeOne Medicines Ltd.
|
31.57% | 0.334 | 5.05% | 2.09x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SOPH
SOPHiA GENETICS SA
|
$12.9M | -$17.3M | -57.5% | -86.58% | -88.76% | -$13.2M |
|
ACIU
AC Immune SA
|
-- | -$19.6M | -72.31% | -75.88% | -1671.93% | -$24.4M |
|
ADXN
Addex Therapeutics Ltd.
|
-- | -$674K | 91.08% | 91.08% | -2836.3% | -$665.6K |
|
CRSP
CRISPR Therapeutics AG
|
-$60.6M | -$132.1M | -23.42% | -26.17% | -14854.78% | -$84.7M |
|
ONC
BeOne Medicines Ltd.
|
$1.2B | $163.3M | 1.43% | 1.92% | 11.55% | $355.1M |
SOPHiA GENETICS SA vs. Competitors
-
Which has Higher Returns SOPH or ACIU?
AC Immune SA has a net margin of -102.87% compared to SOPHiA GENETICS SA's net margin of -1688.87%. SOPHiA GENETICS SA's return on equity of -86.58% beat AC Immune SA's return on equity of -75.88%.
Company Gross Margin Earnings Per Share Invested Capital SOPHSOPHiA GENETICS SA66.32% -$0.30 $124.1M ACIUAC Immune SA-- -$0.20 $84.3M -
What do Analysts Say About SOPH or ACIU?
SOPHiA GENETICS SA has a consensus price target of $7.33, signalling upside risk potential of 46.08%. On the other hand AC Immune SA has an analysts' consensus of $9.61 which suggests that it could grow by 235.06%. Given that AC Immune SA has higher upside potential than SOPHiA GENETICS SA, analysts believe AC Immune SA is more attractive than SOPHiA GENETICS SA.
Company Buy Ratings Hold Ratings Sell Ratings SOPHSOPHiA GENETICS SA4 0 0 ACIUAC Immune SA3 0 0 -
Is SOPH or ACIU More Risky?
SOPHiA GENETICS SA has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison AC Immune SA has a beta of 1.602, suggesting its more volatile than the S&P 500 by 60.243%.
-
Which is a Better Dividend Stock SOPH or ACIU?
SOPHiA GENETICS SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AC Immune SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SOPHiA GENETICS SA pays -- of its earnings as a dividend. AC Immune SA pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SOPH or ACIU?
SOPHiA GENETICS SA quarterly revenues are $19.5M, which are larger than AC Immune SA quarterly revenues of $1.2M. SOPHiA GENETICS SA's net income of -$20M is lower than AC Immune SA's net income of -$19.8M. Notably, SOPHiA GENETICS SA's price-to-earnings ratio is -- while AC Immune SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SOPHiA GENETICS SA is 4.60x versus 56.16x for AC Immune SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SOPHSOPHiA GENETICS SA4.60x -- $19.5M -$20M ACIUAC Immune SA56.16x -- $1.2M -$19.8M
-
Which has Higher Returns SOPH or ADXN?
Addex Therapeutics Ltd. has a net margin of -102.87% compared to SOPHiA GENETICS SA's net margin of -2841.85%. SOPHiA GENETICS SA's return on equity of -86.58% beat Addex Therapeutics Ltd.'s return on equity of 91.08%.
Company Gross Margin Earnings Per Share Invested Capital SOPHSOPHiA GENETICS SA66.32% -$0.30 $124.1M ADXNAddex Therapeutics Ltd.-- -- $13.1M -
What do Analysts Say About SOPH or ADXN?
SOPHiA GENETICS SA has a consensus price target of $7.33, signalling upside risk potential of 46.08%. On the other hand Addex Therapeutics Ltd. has an analysts' consensus of $30.00 which suggests that it could grow by 257.97%. Given that Addex Therapeutics Ltd. has higher upside potential than SOPHiA GENETICS SA, analysts believe Addex Therapeutics Ltd. is more attractive than SOPHiA GENETICS SA.
Company Buy Ratings Hold Ratings Sell Ratings SOPHSOPHiA GENETICS SA4 0 0 ADXNAddex Therapeutics Ltd.0 0 0 -
Is SOPH or ADXN More Risky?
SOPHiA GENETICS SA has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Addex Therapeutics Ltd. has a beta of 1.573, suggesting its more volatile than the S&P 500 by 57.32%.
-
Which is a Better Dividend Stock SOPH or ADXN?
SOPHiA GENETICS SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Addex Therapeutics Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SOPHiA GENETICS SA pays -- of its earnings as a dividend. Addex Therapeutics Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SOPH or ADXN?
SOPHiA GENETICS SA quarterly revenues are $19.5M, which are larger than Addex Therapeutics Ltd. quarterly revenues of $62.3K. SOPHiA GENETICS SA's net income of -$20M is lower than Addex Therapeutics Ltd.'s net income of -$1.6M. Notably, SOPHiA GENETICS SA's price-to-earnings ratio is -- while Addex Therapeutics Ltd.'s PE ratio is 0.77x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SOPHiA GENETICS SA is 4.60x versus 35.97x for Addex Therapeutics Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SOPHSOPHiA GENETICS SA4.60x -- $19.5M -$20M ADXNAddex Therapeutics Ltd.35.97x 0.77x $62.3K -$1.6M
-
Which has Higher Returns SOPH or CRSP?
CRISPR Therapeutics AG has a net margin of -102.87% compared to SOPHiA GENETICS SA's net margin of -11973.12%. SOPHiA GENETICS SA's return on equity of -86.58% beat CRISPR Therapeutics AG's return on equity of -26.17%.
Company Gross Margin Earnings Per Share Invested Capital SOPHSOPHiA GENETICS SA66.32% -$0.30 $124.1M CRSPCRISPR Therapeutics AG-6819.57% -$1.17 $2.1B -
What do Analysts Say About SOPH or CRSP?
SOPHiA GENETICS SA has a consensus price target of $7.33, signalling upside risk potential of 46.08%. On the other hand CRISPR Therapeutics AG has an analysts' consensus of $81.33 which suggests that it could grow by 39.8%. Given that SOPHiA GENETICS SA has higher upside potential than CRISPR Therapeutics AG, analysts believe SOPHiA GENETICS SA is more attractive than CRISPR Therapeutics AG.
Company Buy Ratings Hold Ratings Sell Ratings SOPHSOPHiA GENETICS SA4 0 0 CRSPCRISPR Therapeutics AG12 10 1 -
Is SOPH or CRSP More Risky?
SOPHiA GENETICS SA has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CRISPR Therapeutics AG has a beta of 1.738, suggesting its more volatile than the S&P 500 by 73.75%.
-
Which is a Better Dividend Stock SOPH or CRSP?
SOPHiA GENETICS SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CRISPR Therapeutics AG offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SOPHiA GENETICS SA pays -- of its earnings as a dividend. CRISPR Therapeutics AG pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SOPH or CRSP?
SOPHiA GENETICS SA quarterly revenues are $19.5M, which are larger than CRISPR Therapeutics AG quarterly revenues of $889K. SOPHiA GENETICS SA's net income of -$20M is higher than CRISPR Therapeutics AG's net income of -$106.4M. Notably, SOPHiA GENETICS SA's price-to-earnings ratio is -- while CRISPR Therapeutics AG's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SOPHiA GENETICS SA is 4.60x versus 132.71x for CRISPR Therapeutics AG. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SOPHSOPHiA GENETICS SA4.60x -- $19.5M -$20M CRSPCRISPR Therapeutics AG132.71x -- $889K -$106.4M
-
Which has Higher Returns SOPH or ONC?
BeOne Medicines Ltd. has a net margin of -102.87% compared to SOPHiA GENETICS SA's net margin of 8.84%. SOPHiA GENETICS SA's return on equity of -86.58% beat BeOne Medicines Ltd.'s return on equity of 1.92%.
Company Gross Margin Earnings Per Share Invested Capital SOPHSOPHiA GENETICS SA66.32% -$0.30 $124.1M ONCBeOne Medicines Ltd.83.86% $1.09 $6B -
What do Analysts Say About SOPH or ONC?
SOPHiA GENETICS SA has a consensus price target of $7.33, signalling upside risk potential of 46.08%. On the other hand BeOne Medicines Ltd. has an analysts' consensus of $401.52 which suggests that it could grow by 21.16%. Given that SOPHiA GENETICS SA has higher upside potential than BeOne Medicines Ltd., analysts believe SOPHiA GENETICS SA is more attractive than BeOne Medicines Ltd..
Company Buy Ratings Hold Ratings Sell Ratings SOPHSOPHiA GENETICS SA4 0 0 ONCBeOne Medicines Ltd.18 1 1 -
Is SOPH or ONC More Risky?
SOPHiA GENETICS SA has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison BeOne Medicines Ltd. has a beta of 0.452, suggesting its less volatile than the S&P 500 by 54.771%.
-
Which is a Better Dividend Stock SOPH or ONC?
SOPHiA GENETICS SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BeOne Medicines Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SOPHiA GENETICS SA pays -- of its earnings as a dividend. BeOne Medicines Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SOPH or ONC?
SOPHiA GENETICS SA quarterly revenues are $19.5M, which are smaller than BeOne Medicines Ltd. quarterly revenues of $1.4B. SOPHiA GENETICS SA's net income of -$20M is lower than BeOne Medicines Ltd.'s net income of $125M. Notably, SOPHiA GENETICS SA's price-to-earnings ratio is -- while BeOne Medicines Ltd.'s PE ratio is 637.68x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SOPHiA GENETICS SA is 4.60x versus 7.40x for BeOne Medicines Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SOPHSOPHiA GENETICS SA4.60x -- $19.5M -$20M ONCBeOne Medicines Ltd.7.40x 637.68x $1.4B $125M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 62x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
63
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 40x
Alerts
Buy
54
SMX alert for Dec 5
SMX (Security Matters) Plc [SMX] is up 190.82% over the past day.
Sell
15
HOV alert for Dec 5
Hovnanian Enterprises, Inc. [HOV] is down 0.06% over the past day.
Buy
67
NUTX alert for Dec 5
Nutex Health, Inc. [NUTX] is up 1.89% over the past day.
